Antimicrobial resistance (AMR) is a global health crisis, and Australia is not immune to its effects. As bacteria evolve to resist antibiotics, common infections become harder to treat, posing significant…
Continue readingJuly 2024 marked another pivotal month for the Australian automotive industry, with the latest VFACTS sales data revealing significant shifts in consumer preferences and market dynamics. The market again cracked…
Continue readingIn an era of rapid technological advancement and shifting market dynamics, businesses across all sectors must prepare for significant transformation and disruption. At a recent industry conference, I presented a…
Continue readingAs the first half of the year ends, it’s a good time to reflect on the changes we’re seeing in the automotive market, and how these might play out through…
Continue readingRenewable energy is experiencing a transformative phase worldwide, with unprecedented investments, technological advancements, and policy shifts driving the sector forward. As nations strive to meet climate goals and reduce dependency…
Continue readingAustralia has reached the midpoint of the year, and has recorded another strong sales figure, with 119,659 new vehicles delivered in June. We are however seeing conflicting trends across the…
Continue readingAt Fifth Quadrant, we are constantly embracing innovative tools and technologies to enhance our market research capabilities and provide clients with a greater level of insight. Accordingly, we are early…
Continue readingAs we prepare to release the 2024 edition of our Corporate Fleet Insights Report, we are excited to share a sneak preview of the high-level themes that are shaping the…
Continue readingAustralia’s automotive industry has continued its record-breaking new vehicle sales streak, reaching an all-time record high for the month of May. Despite April dipping back below 100,000 sales (97,202), May…
Continue readingIn our ongoing series on body image and weight issues in Australia, we delve deeper into the use of pharmaceutical interventions like Ozempic and Mounjaro. The GLP1 agonist class of…
Continue reading